ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application.
ASSAY and Drug Development Technologies coverage includes:
Assay design, target development, and high-throughput technologies
Hit to Lead optimization and medicinal chemistry through preclinical candidate selection
Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis
Approaches to assays configured for gene families, inherited, and infectious diseases
Assays and strategies for adapting model organisms to drug discovery
The use of stem cells as models of disease
Translation of phenotypic outputs to target identification
Exploration and mechanistic studies of the technical basis for assay and screening artifacts
The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

This DRRR special section features original papers, application-oriented technology reviews, and reports in methodology and technology application to drug repurposing and redevelopment including:
Designing assays and interpreting output to enable alternate drug target identification
Pathway analysis and bioinformatics to identify and exploit drug promiscuity
In silico technologies to identify alternate drug targets
"Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Bruce Melancon, PhD, University of Notre Dame; and other leading investigators.The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U. View the entire editorial board.

Journal Audience Includes: Drug discovery and assay development scientists, drug delivery and formulation specialists, molecular and behavioral pharmacologists, pharmaceutical and biotechnology researchers, and disease foundation advocates, among others.

Editor-in-Chief
Bruce Melancon, PhD
Vanderbilt Center for Neuroscience Drug Discovery
Franklin, TN
Editor, Drug Repurposing, Rescue, and 
Repositioning (DRRR) Advisory Board
Hermann A. M. Mucke, PhD
CEO, H. M. Pharma Consultancy
Enenkelstrasse 28/32
A-1160 Wien (Vienna), Austria
Phone: +43 664 101 0121
Fax: +43 664 77 101 0121
h.mucke@hmpharmacon.com
Editor, Society for Biomolecular Imaging and Informatics Special Issues
Myles Fennell, PhD 
Memorial Sloan Kettering Cancer Center
New York, NY
Associate Editors
Michelle Arkin, PhD
University of California
San Francisco, CA
Haian Fu, PhD
Emory University School of Medicine
Atlanta, GA
Thomas Lundbäck, PhD
Karolinska Institutet        
Stockholm, Sweden
Founding Editor
Jim Inglese, PhD
Bethesda, MD
Literature Editors   
Doug Auld, PhD
Novartis Institutes for BioMedical Research 
Anton Simeonov, PhD
Bethesda, MD  

Editorial Board
Stephen J. Benkovic, PhD
Pennsylvania State University
University Park, PA
*Laura Berliocchi, PhD
Magna Graecia University
Catanzaro, Italy
Leo S. Bleicher, AB
Cepheus Information Systems
San Diego, CA
*Bruce E. Bloom, JD, DDS
Healx, Ltd.
Evanston, IL

Susan Catalano, PhD
Cognition Therapeutics, Inc. 
Pittsburgh, PA
*Harsh Chauhan, PhD
Creighton University
Omaha, NE

Daniel Chelsky, PhD
Caprion Pharmaceuticals
Montreal, Quebec
Canada
Ken Chih-Chien Cheng, PhD 
Bethesda, MD  

Namjin Chung, PhD
Bristol-Myers Squibb Co.
Hopewell, NJ
Richard Cummings, PhD 
Constellation Pharmaceuticals 
Cambridge, MA
Hakim Djaballah, PhD
Keren Therapeutics 
Scarsdale, NY
Richard M. Eglen, PhD
Corning Life Sciences
Tewksbury, MA
*Stephen C. Ekker, PhD
Mayo Clinic
Rochester, MN
Darryl Falzarano, PhD
University of Saskatchewan
Saskatoon, SK
Frank Fan, PhD
Promega Corporation
Madison, WI

Thomas L. Fare, PhD
Merck & Co., Inc.
Lansdale, PA  
Dan Fitzpatrick, PhD
Amgen, Inc.
Thousand Oaks, CA
*Georgios V. Gkoutos, BSc, MSc, PhD, DIC    
University of Aberystwyth
Dyfed, UK

J. Fraser Glickman, MPH, PhD
Rockefeller University 
New York, NY
Samuel Hasson, PhD 
Amgen Neuroscience  
Cambridge, MA
Christopher Heise, PhD
Genentech Inc.
South San Francisco, CA 
Ilkka Hemmilä, PhD
PerkinElmer Life Sciences
Turku, Finland
Tod P. Holler, PhD
University of Michigan
Ann Arbor, MI
Paul A. Johnston, PhD
University of Pittsburgh School of Medicine
Pittsburgh, PA
Robert J. Lefkowitz, MD
HHMI/Duke University Medical Center
Durham, NC
Jay Liu, PhD 
Rugen Therapeutics 
Shanghai, China
Wai Hong (Kevin) Lo, PhD
University of Connecticut Health Center
Farmington, CT
Ralph R. Martel, PhD
High Throughput Genomics, Inc.
Tucson, AZ

Lorenz Mayr, PhD
Novartis Pharma AG / NIBR
Basel, Switzerland
Patricia McDonald, PhD
The Scripps Research Institute 
Scripps Florida
Jupiter, FL
Andrew D. Napper, PhD 
Evotec, Inc.
Princeton, NJ

Walter D. Niles, PhD
Aurora Biotechnologies, Inc.
La Jolla, CA 
Kevin R. Oldenburg, PhD
MatriCal
Spokane, WA
Hiroyuki Osada, PhD 
RIKEN Advanced Science Institute
Saitama, Japan

Young-Whan Park, PhD
National OncoVenture at National Cancer Center
Gyeonggi-do, Korea
*Michael P. Pollastri, PhD
Northeastern University
Boston, MA

Jeffrey H. Price, MD
Burnham Institute for Medical Research
La Jolla, CA 
John R. Raymond, MD
Medical College of Wisconsin
Milwaukee, WI

Bryan Roth, MD, PhD
University of North Carolina
Chapel Hill, NC
*E. Mitchell Seymour, PhD, RAC
R&D Advisors LLC
Michigan Institute for Clinical and Health Research
Ann Arbor, MI
Caroline E. Shamu, PhD
Harvard Medical School
Boston, MA
Kaylene J. Simpson, PhD
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia
Gary Skinner, PhD
Illumina United Kingdom
Essex, United Kingdom

*Sharon F. Terry, MA
Genetic Alliance
Washington, DC
Jeffrey H. Toney, PhD
Kean University
Union, NJ
Richard B. van Breemen, PhD
University of Illinois College of Pharmacy
Chicago, IL
Henry VanBrocklin, PhD
University of California
San Francisco, CA
Christian R. Voolstra, PhD
Red Sea Research Center
King Abdullah University of Science and Technology (KAUST)
Thuwal, Saudi Arabia

Jun Wang, PhD
Lynk Pharmaceuticals
Shanghai, China

C. David Weaver, PhD
Vanderbilt Medical School
Nashville, TN
Holly Yin, PhD
City of Hope National Medical Center
Duarte, CA
Guido JR Zaman, PhD
Netherlands Translational Research Center B.V.
Oss, The Netherlands

Zhong Zhong, PhD
GlaxoSmithKline R & D China
Shanghai, China
 
*(DRRR) Advisory Board Member
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.